A carregar...
T315I clone selection in a Ph+ all patient under low‐dose ponatinib maintenance
We report here the clinical course of a Ph+ ALL patient who was treated with ponatinib 15 mg/day, as maintenance therapy, and developed a BCR‐ABL T315I mutation leading to ALL relapse. This clonal evolution was reversed, without adverse effects, by increasing ponatinib to 45 mg/day. To our knowledge...
Na minha lista:
| Publicado no: | Clin Case Rep |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley and Sons Inc.
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5538043/ https://ncbi.nlm.nih.gov/pubmed/28781850 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ccr3.1032 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|